
SYNTHESIS OF 3,4-DISUBSTITUTED-1-β-D-RIBOFURANOSYLPYRAZOLO[3,4-d]PYRIMIDINES

Howard B. Cottam, Charles R. Petrie, <u>Ganapathi R. Revankar</u> and Roland K. Robins Cancer Research Center, Department of Chemistry, Brigham Young University, Provo, UT 84602

Renewed interest has been generated recently in the chemistry and biochemistry of pyrazolo- $[3,4-\underline{d}]$ pyrimidine nucleosides. Allopurinol ribonucleoside ($\underline{1}$, R = H) exhibits antileishmanial activity.¹⁻³ In addition to \underline{L} . <u>braziliensis</u>, 4-aminopyrazolo[3,4-<u>d</u>]pyrimidine nucleoside (4-APP riboside, $\underline{2}$, R = H) was found to be active against \underline{T} . <u>cruzi</u> and \underline{T} . <u>rangeli</u> <u>in vitro</u>. Recently, we reported a convenient synthesis of 6-aminoallopurinol riboside and related 4,6-disubstituted pyrazolo[3,4-<u>d</u>]pyrimidine nucleosides.⁴ We now wish to report on the synthesis of selected 3-substituted allopurinol/4-APP nucleosides of the general formulas <u>1</u> and <u>2</u>.



Glycosylation of the TMS 3-bromoallopurinol with acylated β -<u>D</u>-ribofuranose in presence of a Lewis-acid catalyst gave the protected 1-ribosyl-3-bromoallopurinol as the major product, which on reaction with a number of nucleophiles produced a variety of 3-substituted allopurinol ribosides. A similar glycosylation of 3-methylthioallopurinol and subsequent deprotection provided <u>1</u> (R = SCH₃). However, direct ribosylation and deprotection of 3-bromo-4-APP gave <u>2</u> (R = Br). Chlorination of blocked 3-bromoallopurinol riboside with phosphoryl chloride followed by amination provided the hitherto inaccessible 3-amino-4-APP riboside <u>2</u> (R = NH₂). Reaction of the TMS 3-cyanoallopurinol with blocked glycone gave the blocked 3-cyanoallopurinol riboside in which the nitrile function was available for further transformations. The detailed synthetic studies leading to these analogs and their structural elucidation will be presented.

This investigation was supported by U.S. Army Medical Research and Development Command Contract Number DAMD17-82-C-2224.

References

- D.J. Nelson, S.W. LaFon, J.V. Tuttle, W.H. Miller, R.L. Miller, T.A. Krenitsky, G.B. Elion, R.L. Berens and J.J. Marr, <u>J. Biol. Chem.</u>, <u>254</u>, 11544 (1979).
- 2. R.L. Berens, J.J. Marr, D.J. Nelson and S.W. LaFon, Biochem. Pharmacol., 29, 2397 (1980).
- 3. J.D. Berman, L.S. Lee, R.K. Robins and G.R. Revankar, mitted (1983). <u>Antimicrob. Agents Chemother</u>., sub-
- 4. H.B. Cottam, G.R. Revankar and R.K. Robins, Nucleic Acids Res., 11, 871 (1983).